In a groundbreaking move, the Goods and Services Tax (GST) Council recently announced significant reforms during its 56th meeting, sparking enthusiasm among pharma industry experts who foresee a positive impact on the accessibility of life-saving drugs and the enhancement of public health.
Under the astute leadership of Finance Minister Nirmala Sitharaman, the GST Council streamlined the tax structure by consolidating the existing four slabs into two, eliminating the 12% and 28% rates while retaining the 5% and 18% slabs. This pivotal decision is set to benefit the healthcare sector immensely, particularly in reducing the tax burden on life-saving drugs, health-related products, and certain medical devices, with rates slashed from 12% or 18% to 5% or nil.
The revised GST rates are scheduled to come into effect from September 22, marking a new era of affordability in healthcare. The Indian Pharmaceutical Alliance (IPA) hailed this move as a critical step in fostering growth and ensuring the accessibility of medicines by placing them in the 5% slab. Sudarshan Jain, Secretary General of IPA, emphasized the importance of aligning GST rates on essential pharmaceutical components to 5%, a measure that promises to curb tax inversion, enhance working capital, boost domestic manufacturing, and solidify India’s stature as a global pharmaceutical hub.
Amidst these developments, the Association of Indian Medical Device Industry (AiMeD) expressed its approval of the government’s decision to reduce GST rates from 12% to 5%. Rajiv Nath, the Co-Ordinator of AiMeD Forum, highlighted the need for expedited refunds on accumulated GST due to inverted tax structures, echoing the sentiments of industry players aiming for global competitiveness akin to countries like Australia, Singapore, and Canada. Additionally, AiMeD hopes for a grace period for transitioning packaging materials and intends to pass on the GST benefits to end consumers by adjusting Maximum Retail Prices (MRP) accordingly.
Further enhancing the affordability and accessibility of healthcare, the government also zeroed out GST on individual health and life insurance premiums, previously taxed at 18%. This move is poised to make insurance more economical for the general populace, expanding coverage nationwide. All individual life and health insurance policies, including term life, Unit Linked Insurance Plans (ULIPs), endowment plans, and their reinsurance, now fall under the nil GST category, offering relief to policyholders and encouraging wider insurance adoption.
As the healthcare landscape undergoes this transformative shift, stakeholders anticipate a cascade of positive outcomes, ranging from reduced healthcare costs to an uptick in insurance penetration. The holistic impact of these GST reforms extends beyond mere tax adjustments; it represents a paradigm shift towards a more inclusive, affordable, and sustainable healthcare ecosystem.
The Impact of GST Reforms in Healthcare:
- Enhanced affordability of life-saving drugs and medical devices
- Strengthening of domestic manufacturing and India’s global pharmaceutical standing
- Facilitation of expedited GST refunds for industry competitiveness
- Expansion of insurance coverage through reduced GST on premiums
As the nation embraces these progressive reforms, the future of healthcare looks brighter and more accessible than ever before. The convergence of policy changes, industry collaboration, and consumer-centric initiatives heralds a new era of healthcare affordability and inclusivity, setting the stage for a healthier and more prosperous India.
Read more on indiatribune.com